Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC, Pulmonary-Allergy to review Rx rhinitis switch candidates.

This article was originally published in The Tan Sheet

Executive Summary

VANCENASE AQ AND NASALCROM Rx-TO-OTC SWITCHES TO BE REVIEWED BY NDAC and FDA's Pulmonary-Allergy Drugs Advisory Committee on October 10-11 as treatments for seasonal allergic rhinitis. Schering-Plough is seeking to switch Vancenase AQ nasal inhaler, which contains beclomethasone dipropionate, an anti-inflammatory steroid. Johnson & Johnson's McNeil Consumer is sponsoring the Nasalcrom (cromolyn sodium) switch; prescription Nasalcrom is manufactured and sold by Fisons. The two products would be the first inhaled anti-inflammatory agents to be switched to over-the-counter status.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel